InspireMD Inc. (NSPR) News
InspireMD Inc. (NSPR)
Today's Latest Price: $0.60 USD
Updated Jan 15 8:00pm
Add NSPR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 335 in Miscellaneous
See all "A" rated Strong Buy stocks
StocksNews Articles for NSPR
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NSPR News From Around the Web
Below are the latest news stories about InspireMD Inc that investors may wish to consider to help them evaluate NSPR as an investment opportunity.
Insider Buying: InspireMD Inc (NYSEAMERICAN:NSPR) Director Buys $100,000.35 in StockInspireMD Inc (NYSEAMERICAN:NSPR) Director Gary S. Roubin acquired 222,223 shares of the stock in a transaction on Friday, October 16th. The stock was purchased at an average cost of $0.45 per share, with a total value of $100,000.35. The transaction was disclosed in a document filed with the SEC, which is available through this link. […] |
InspireMD Inc (NYSEAMERICAN:NSPR) Director Buys $100,000.35 in StockInspireMD Inc (NYSEAMERICAN:NSPR) Director Gary S. Roubin purchased 222,223 shares of the stock in a transaction that occurred on Friday, October 16th. The shares were purchased at an average price of $0.45 per share, with a total value of $100,000.35. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can […] |
Gary S. Roubin Buys 222,223 Shares of InspireMD Inc (NYSEAMERICAN:NSPR) StockInspireMD Inc (NYSEAMERICAN:NSPR) Director Gary S. Roubin purchased 222,223 shares of InspireMD stock in a transaction that occurred on Friday, October 16th. The shares were purchased at an average price of $0.45 per share, for a total transaction of $100,000.35. The transaction was disclosed in a filing with the SEC, which is available through the […] |
InspireMD (NYSEAMERICAN:NSPR) Stock Price Down 6.6%InspireMD Inc (NYSEAMERICAN:NSPR) was down 6.6% during trading on Tuesday . The stock traded as low as $0.37 and last traded at $0.39. Approximately 1,710,846 shares were traded during trading, a decline of 11% from the average daily volume of 1,928,471 shares. The stock had previously closed at $0.42. Several equities research analysts have commented […] |
InspireMD Inc (NYSEAMERICAN:NSPR) Director Gary S. Roubin Acquires 222,223 Shares of StockInspireMD Inc (NYSEAMERICAN:NSPR) Director Gary S. Roubin bought 222,223 shares of the stock in a transaction dated Friday, October 16th. The stock was bought at an average price of $0.45 per share, with a total value of $100,000.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC […] |
InspireMD Inc (NYSEAMERICAN:NSPR) Director Purchases $100,000.35 in StockInspireMD Inc (NYSEAMERICAN:NSPR) Director Gary S. Roubin bought 222,223 shares of the business’s stock in a transaction on Friday, October 16th. The stock was acquired at an average cost of $0.45 per share, for a total transaction of $100,000.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is […] |
InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent SystemAdvancing the CARENET-III study of CGuard System for Stroke Prevention in the United StatesTEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Dr. Christina Brennan as a strategic advisor to the company to assist with planning and execution of a pivotal study of the CGuard™ Carotid Stent System, CARENET-III, for prevention of stroke in patients in the United States. The company recently announced that it had received approval from the FDA for the company to proceed with this pivotal study. “We are pleased to have Dr. Brennan join the team as we advance our efforts of planning and executi... |
InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent SystemIDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United StatesTEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the U.S. Food and Drug Administration (“FDA” or “the Agency”) has granted approval for the company to proceed with a pivotal study of the CGuard™ Carotid Stent System, CARENET-III, for prevention of stroke in patients in the United States. “This is a key milestone in the history of our company as it helps pave the way for us to initiate a clinical trial of CGuard EPS for addressing Carotid Artery Disease and preventing s... |
UPDATE: InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate UpdateConference Call to be held Wednesday, August 5, 2020 at 8:30am ETTEL AVIV, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on Wednesday, August 5, 2020 at 8:00 AM ET. Management will host a conference call at 8:30AM ET, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question and answer session. Participants are asked to pre-register for the call through the following link: http://dpregister.com/10146840. Please note that registered participants will receive their di... |
InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate UpdateConference Call to be held Thursday, August 5, 2020 at 8:30am ET |